Summary
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and
dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults
with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a
treatment regimen most likely to result in clinical efficacy while maintaining a favorable
safety profile.